Is it time to believe in the telecom giant?
BCE Inc. has not been a stock to own for capital gains in recent years, but you could count on a generous dividend that got bumped up a bit every year. The dividend’s still growing, but BCE ’s share price has fallen by 14 per cent this year and 28 per cent in the past 12 months. The dividend yield, long in the 5- to 6-per-cent range, now approaches 9 per cent. If high yields are a warning, this one’s an air raid siren dialled up to 11.
A separate Morningstar equity analyst report dated April 3 slapped a five-star rating on BCE with a fair value estimate of $60. A headline in the report: Rogers, Telus, and BCE: The Selloff is Overdone; We Favor Rogers, but All Three Look Like Bargains. Most brokers and investing websites offer a consensus of analyst ratings for a stock. The consensus rating for BCE is a “hold”, based on 83 per cent of analysts covering the stock saying hold and 17 per cent saying “buy.” None have a “sell” on the stock.
Cent Stock Dividend BCE Company Hold Report CFRA Morningstar Globe
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AVAX’s rare green signal after price crash – To buy or not to buyLosing 8.83% of its value in the last 24 hours led Avalanche's [AVAX] price to decline below $50. However, AMBCrypto's analysis showed
Read more »
Amazon's Having A Big Spring Sale: Here's What Pet Owners Should Actually BuyPounce on the biggest deals of the season, from cozy pet beds and fun-filled toys to tasty treats and grooming supplies.
Read more »
39 Kids Things To Buy During Amazon's Big Spring SaleGet ready for Amazon's March toy mania, where the fun never stops!
Read more »
ONDO explodes 95% with whales’ help: Time to buy?RWA token Ondo Finance [ONDO] has continued its upward march, surging by more than 28% in the last 24 hours,
Read more »
Gold is a buy, but bonds may be a bustIn Monday's installment of Good Buy or Goodbye, Sound Planning Group CEO David Stryzewski joins Yahoo Finance anchor Josh Lipton to discuss why he recommends...
Read more »
Novo Nordisk to buy Cardior Pharmaceuticals for up to $1.1 billionDenmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its...
Read more »